Rigel Pharmaceuticals (RIGL) Common Equity (2010 - 2026)

Rigel Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $399.9 million for Q1 2026.

• In Q1 2026, Common Equity rose 2053.81% year-over-year to $399.9 million; the TTM figure through Mar 2026 stood at $399.9 million (up 2053.81% YoY), while the FY2025 annual figure was $391.5 million, up 11806.33% from the prior year.
• Common Equity was $399.9 million for Q1 2026 at Rigel Pharmaceuticals, up from $391.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $399.9 million in Q1 2026 to a low of -$31.8 million in Q3 2023.
• Historically, Common Equity has averaged $46.7 million across 5 years, with a median of -$13.6 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Common Equity sank 664.62% in 2023, then surged 11806.33% in 2025.
• A 5-year view of Common Equity shows it stood at -$13.6 million in 2022, then tumbled by 110.37% to -$28.6 million in 2023, then surged by 111.48% to $3.3 million in 2024, then soared by 11806.33% to $391.5 million in 2025, then gained by 2.15% to $399.9 million in 2026.
• The last three Common Equity figures came in at $399.9 million (Q1 2026), $391.5 million (Q4 2025), and $117.6 million (Q3 2025), per Business Quant data.